Rankings Pharma & medtech Aurora Cannabis
Aurora Cannabis
46
15070100
A view of the same findings, not a new score. How it works
The model found several serious problems. That does not mean the stock will fall.
Biggest deductions
- Margin−10
- Capital allocation−6
- Multiples vs history and peers−5
Strengths
- Net cash+3
- International medical growth+1
How the score is built
From 100 to 46, step by step: points off for the business, the price and the cracks, back for documented strengths, then three data adjustments.
Start
Score
Hover or select a step to see what drove it. Steps with findings open them below.
Key numbers
As of 2 Nov 2026. Analyst targets tend to be optimistic; read upside as a hint, not a forecast.
- Price
- 5.89 CAD
- Median analyst target
- 5.65 CAD
- Upside to median
- −4.1%
- Analysts
- 4
- Target range
- 4.00 – 8.00 CAD
- 52-week change
- −15%
- P/E (trailing)
- n/a
- Forward P/E
- n/a
- PEG
- n/a
Findings
Every deduction and every plus, with its source. Open a step to read them.
Business
Is the company getting stronger, not just bigger? · 4 findings−23 of −30
- −10MarginOperating loss of CAD 43.5m TTM (operating margin −13.8%), and adjusted EBITDA fell 68% to 3.4m in Q1 FY27; adjusted gross margin fell from 64% to 58%. The loss is counted only here.
- −4Quality of growthRevenue fell 9% in Q1 FY27 (CAD 67.6m); the consumer segment is being wound down (-73%), and consensus expects -6.9% for FY27. Only international medical cannabis grows (+17%).
- −6Capital allocationFCF -CAD 51.2m TTM with capex of 23m and the purchase of Safari Flower; historically billions have been lost (net loss 1.72bn in FY22 and 817m in FY23), and book value per share has fallen from CAD 22.23 to 8.33 since 2022.
- −3MoatCannabis is a commodity-like product with price pressure; EU-GMP certification and international distribution give an advantage over smaller Canadian producers, but not pricing power.
Price
Today's multiples against the company's own history and its peers. · 1 finding−5 of −35
- −5Multiples vs history and peersEV/Sales 0.91 vs 0.89-1.45 in FY23-26 and P/B 0.69 vs 0.51-0.62; Organigram trades at EV/Sales 0.91 and SNDL at 0.45. The price is up about 41% in 3 months without better figures, and the analysts' median (CAD 5.00) is below the price.
Cracks
Cash flow, customers, debt, insiders, guidance and what sits behind the headline numbers. · 4 findings−14 of −35
- −5Regulation in CanadaCanada's federal reimbursement programme (veterans) cut rates by about 30% from 1/4-2026; Canadian medical revenue fell 25% to CAD 20.7m in Q1 FY27.
- −4Dilution (ATM)ATM programme of up to USD 100m from 4/2-2026; 2.2m shares sold in FY26 and 1.58m in Q1 FY27 plus 2.42m shares for the Safari acquisition. The share count rose 7.5% in a quarter.
- −3Dependence on EuropeEurope accounts for CAD 139m of CAD 314m in revenue TTM; growth rests on German and Polish medical demand, where regulation and import prices can change quickly.
- −2Short interest11.5% of the shares are sold short on the Nasdaq listing (6.6 days to cover), a clearly skeptical signal.
Plus
Only documented strengths. · 2 findings+4 of +15
- +3Net cashCash, cash equivalents and short-term investments of CAD 149.1m at 30/6-2026 and no bank debt (only approx. 23m in leasing).
- +1International medical growthInternational medical revenue +17% to CAD 43.3m; Safari Flower received three-year EU-GMP certification on 23/7-2026.
Caveats
What the score does not capture, or where the data is weak.
Penny deep dive (the price is above DKK 3). Industry set to Medicine & medtech as the closest choice (medical cannabis; no cannabis category). Price CAD 5.58 and 64.86m shares (market cap about CAD 362m) from stockanalysis 2/10-2026; Nordnet showed DKK 1,740m. The company reports cash, equivalents and short-term investments of CAD 149.1m at 30/6-2026, while stockanalysis shows only 100.0m; I use the company's figure. Debt of 22.7m is primarily leasing; no bank debt. Aurora has no US business, so US rescheduling only affects sentiment. CEO/CFO names and track record are not confirmed for 2026.
Also in Pharma & medtech
The highest scores in the same industry.
